Skip to main content
Top
Published in: Archives of Dermatological Research 4/2012

01-05-2012 | Short Communication

Bone mineral metabolism in patients with neurofibromatosis type 1 (von Recklingausen disease)

Authors: Luigi Petramala, Sandra Giustini, Laura Zinnamosca, Cristiano Marinelli, Luciano Colangelo, Giuseppina Cilenti, Maria Chiara Formicuccia, Emilio D’Erasmo, Stefano Calvieri, Claudio Letizia

Published in: Archives of Dermatological Research | Issue 4/2012

Login to get access

Abstract

The neurofibromatosis type 1 (NF1) is characterized by specific cutaneous features (neurofibromas, “café-au-lait” spots of the skin) and alterations of several tissue (nervous, vascular) and bone deformities, such as scoliosis, congenital pseudoarthrosis and bone dysplasia of tibia. Moreover, several studies have shown systemic involvement of bone tissue in NF1 patients, leading to reduced bone mass. The aim of our study was to evaluate some bone mineral metabolism parameters before and after calcium and vitamin D supplementation in NF1 patients. We evaluated in 70 NF1 consecutive patients the mineral metabolism and bone mineral density compared with 40 normal subjects. We showed bone alterations in 35% of patients and the increase of bone formation markers, such as bone isoenzyme of alkaline phosphatase (41.2 ± 15.5 vs. 25.6 ± 8.7 UI; P < 0.05, respectively) and osteocalcin (18.1 ± 5.6 vs. 7.6 ± 1.9 ng/ml; P < 0.05) and reduction of circulating levels of (25OH)-vitamin D (21.8 ± 12.3 ng/ml) with an high percentage of hypovitaminosys D (>60%). Moreover, we revealed a significant reduction of bone mass density at spine (L1–L4) (0.935 ± 0.13 vs. 1.110 ± 0.17 g/cm2; P < 0.001) and femoral neck side (0.765 ± 0.09 vs. 0.839 ± 0.12 g/cm2; P < 0.02), with high prevalence of osteopenia (44%) and osteoporosis (18%). After 12 months of calcium (1,200 mg/die) and cholecalciferol (800 UI/die) supplementation, we found a significant increase of (25) OH-vitamin D level (21.8 ± 12.3 vs. 35 ± 13 ng/ml; P < 0.01), without changes in bone mass density. In conclusion, NF1 patients may present a mineral bone involvement, with vitamin D deficiency; calcium and vitamin D supplementation is necessary to restore these bone mineral metabolic alterations.
Literature
1.
go back to reference Abdel-Wanis M, Kawahara N (2002) Hypophosphatemic osteomalacia in neurofibromatosis 1: hypotheses for pathogenesis and higher incidence of spinal deformity. Med Hypotheses 59:183–185PubMedCrossRef Abdel-Wanis M, Kawahara N (2002) Hypophosphatemic osteomalacia in neurofibromatosis 1: hypotheses for pathogenesis and higher incidence of spinal deformity. Med Hypotheses 59:183–185PubMedCrossRef
2.
go back to reference Adami S, Bertoldo F, Brandi ML, Cepollaro C, Filipponi P, Fiore E, Frediani B, Giannini S, Gonnelli S, Isaia GC, Luisetto G, Mannarino E, Marcocci C, Masi L, Mereu C, Migliaccio S, Minisola S, Nuti R, Rini G, Rossini M, Varenna M, Ventura L, Bianchi G, Società Italiana dell’Osteoporosi, del Metabolismo Minerale e delle Malattie dello Scheletro (2009) Guidelines for the diagnosis, prevention and treatment of osteoporosis. Reumatismo 61:260–284 Adami S, Bertoldo F, Brandi ML, Cepollaro C, Filipponi P, Fiore E, Frediani B, Giannini S, Gonnelli S, Isaia GC, Luisetto G, Mannarino E, Marcocci C, Masi L, Mereu C, Migliaccio S, Minisola S, Nuti R, Rini G, Rossini M, Varenna M, Ventura L, Bianchi G, Società Italiana dell’Osteoporosi, del Metabolismo Minerale e delle Malattie dello Scheletro (2009) Guidelines for the diagnosis, prevention and treatment of osteoporosis. Reumatismo 61:260–284
3.
go back to reference Asthagiri AR, Parry DM, Butman JA, Kim HJ, Tsilou ET, Zhuang Z, Lonser RR (2009) Neurofibromatosis type 2. Lancet 373:1974–1986PubMedCrossRef Asthagiri AR, Parry DM, Butman JA, Kim HJ, Tsilou ET, Zhuang Z, Lonser RR (2009) Neurofibromatosis type 2. Lancet 373:1974–1986PubMedCrossRef
4.
go back to reference Atit RP, Crowe MJ, Greenhalgh DG, Wenstrup RJ, Ratner N (1999) The Nf1 tumor suppressor regulates mouse skin wound healing, fibroblast proliferation, and collagen deposited by fibroblasts. J Invest Dermatol 112:835–842PubMedCrossRef Atit RP, Crowe MJ, Greenhalgh DG, Wenstrup RJ, Ratner N (1999) The Nf1 tumor suppressor regulates mouse skin wound healing, fibroblast proliferation, and collagen deposited by fibroblasts. J Invest Dermatol 112:835–842PubMedCrossRef
5.
go back to reference Bollag G, Clapp DW, Shih S, Adler F, Zhang YY, Thompson P, Lange BJ, Freedman MH, McCormick F, Jacks T, Shannon K (1996) Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet 12:144–148PubMedCrossRef Bollag G, Clapp DW, Shih S, Adler F, Zhang YY, Thompson P, Lange BJ, Freedman MH, McCormick F, Jacks T, Shannon K (1996) Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet 12:144–148PubMedCrossRef
6.
go back to reference Brunetti-Pierri N, Doty SB, Hicks J, Phan K, Mendoza-Londono R, Blazo M, Tran A, Carter S, Lewis RA, Plon SE, Phillips WA, O’Brian Smith E, Ellis KJ, Lee B (2008) Generalized metabolic bone disease in neurofibromatosis type I. Mol Genet Metab 94:105–111PubMedCrossRef Brunetti-Pierri N, Doty SB, Hicks J, Phan K, Mendoza-Londono R, Blazo M, Tran A, Carter S, Lewis RA, Plon SE, Phillips WA, O’Brian Smith E, Ellis KJ, Lee B (2008) Generalized metabolic bone disease in neurofibromatosis type I. Mol Genet Metab 94:105–111PubMedCrossRef
7.
go back to reference Cho TJ, Seo JB, Lee HR, Yoo WJ, Chung CY, Choi IH (2008) Biologic characteristics of fibrous hamartoma from congenital pseudarthrosis of the tibia associated with neurofibromatosis type 1. J Bone Joint Surg Am 90:2735–2744PubMedCrossRef Cho TJ, Seo JB, Lee HR, Yoo WJ, Chung CY, Choi IH (2008) Biologic characteristics of fibrous hamartoma from congenital pseudarthrosis of the tibia associated with neurofibromatosis type 1. J Bone Joint Surg Am 90:2735–2744PubMedCrossRef
8.
go back to reference Crawford AH Jr, Bagamery N (1986) Osseous manifestations of neurofibromatosis in childhood. J Pediatr Orthop 6:72–88PubMedCrossRef Crawford AH Jr, Bagamery N (1986) Osseous manifestations of neurofibromatosis in childhood. J Pediatr Orthop 6:72–88PubMedCrossRef
9.
go back to reference Dulai S, Briody J, Schindeler A, North KN, Cowell CT, Little DG (2007) Decreased bone mineral density in neurofibromatosis type 1: results from a pediatric cohort. J Pediatr Orthop 27:472–475PubMedCrossRef Dulai S, Briody J, Schindeler A, North KN, Cowell CT, Little DG (2007) Decreased bone mineral density in neurofibromatosis type 1: results from a pediatric cohort. J Pediatr Orthop 27:472–475PubMedCrossRef
10.
go back to reference Elefteriou F, Benson MD, Sowa H, Starbuck M, Liu X, Ron D, Parada LF, Karsenty G (2006) ATF4 mediation of NF1 functions in osteoblast reveals a nutritional basis for congenital skeletal dysplasiae. Cell Metab 4:441–451PubMedCrossRef Elefteriou F, Benson MD, Sowa H, Starbuck M, Liu X, Ron D, Parada LF, Karsenty G (2006) ATF4 mediation of NF1 functions in osteoblast reveals a nutritional basis for congenital skeletal dysplasiae. Cell Metab 4:441–451PubMedCrossRef
12.
go back to reference Friedman JM (2002) Neurofibromatosis 1: clinical manifestations and diagnostic criteria. J Child Neurol 17:548–554PubMedCrossRef Friedman JM (2002) Neurofibromatosis 1: clinical manifestations and diagnostic criteria. J Child Neurol 17:548–554PubMedCrossRef
13.
go back to reference Gutmann DH, Wood DL, Collins FS (1991) Identification of the neurofibromatosis type 1 gene product. Proc Natl Acad Sci USA 88:9658–9662PubMedCrossRef Gutmann DH, Wood DL, Collins FS (1991) Identification of the neurofibromatosis type 1 gene product. Proc Natl Acad Sci USA 88:9658–9662PubMedCrossRef
14.
go back to reference Heervä E, Alanne MH, Peltonen S, Kuorilehto T, Hentunen T, Väänänen K, Peltonen J (2010) Osteoclasts in neurofibromatosis type 1 display enhanced resorption capacity, aberrant morphology, and resistance to serum deprivation. Bone 47:583–590PubMedCrossRef Heervä E, Alanne MH, Peltonen S, Kuorilehto T, Hentunen T, Väänänen K, Peltonen J (2010) Osteoclasts in neurofibromatosis type 1 display enhanced resorption capacity, aberrant morphology, and resistance to serum deprivation. Bone 47:583–590PubMedCrossRef
15.
go back to reference Hermanns-Sachweh B, Senderek J, Alfer J, Klosterhalfen B, Büttner R, Füzesi L, Weber M (2005) Vascular changes in the periosteum of congenital pseudarthrosis of the tibia. Pathol Res Pract 201(4):305–312PubMedCrossRef Hermanns-Sachweh B, Senderek J, Alfer J, Klosterhalfen B, Büttner R, Füzesi L, Weber M (2005) Vascular changes in the periosteum of congenital pseudarthrosis of the tibia. Pathol Res Pract 201(4):305–312PubMedCrossRef
16.
go back to reference Huson SM, Harper PS, Compston DA (1988) Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales. Brain 111:1355–1381PubMedCrossRef Huson SM, Harper PS, Compston DA (1988) Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales. Brain 111:1355–1381PubMedCrossRef
17.
go back to reference Illés T, Halmai V, de Jonge T, Dubousset J (2001) Decreased bone mineral density in neurofibromatosis-1 patients with spinal deformities. Osteoporos Int 12:823–827PubMedCrossRef Illés T, Halmai V, de Jonge T, Dubousset J (2001) Decreased bone mineral density in neurofibromatosis-1 patients with spinal deformities. Osteoporos Int 12:823–827PubMedCrossRef
18.
go back to reference Kanis JA (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. Osteoporos Int 4:368–381PubMedCrossRef Kanis JA (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. Osteoporos Int 4:368–381PubMedCrossRef
19.
go back to reference Klein BY, Rojansky N, Gal I, Shlomai Z, Liebergall M, Ben-Bassat H (1995) Analysis of cell-mediated mineralization in culture of bone-derived embryonic cells with neurofibromatosis. J Cell Biochem 57:530–542PubMedCrossRef Klein BY, Rojansky N, Gal I, Shlomai Z, Liebergall M, Ben-Bassat H (1995) Analysis of cell-mediated mineralization in culture of bone-derived embryonic cells with neurofibromatosis. J Cell Biochem 57:530–542PubMedCrossRef
20.
go back to reference Klose A, Ahmadian MR, Schuelke M, Scheffzek K, Hoffmeyer S, Gewies A, Schmitz F, Kaufmann D, Peters H, Wittinghofer A, Nürnberg P (1998) Selective disactivation of neurofibromin GAP activity in neurofibromatosis type 1. Hum Mol Genet 7:1261–1268PubMedCrossRef Klose A, Ahmadian MR, Schuelke M, Scheffzek K, Hoffmeyer S, Gewies A, Schmitz F, Kaufmann D, Peters H, Wittinghofer A, Nürnberg P (1998) Selective disactivation of neurofibromin GAP activity in neurofibromatosis type 1. Hum Mol Genet 7:1261–1268PubMedCrossRef
21.
go back to reference Kolanczyk M, Kossler N, Kühnisch J, Lavitas L, Stricker S, Wilkening U, Manjubala I, Fratzl P, Spörle R, Herrmann BG, Parada LF, Kornak U, Mundlos S (2007) Multiple roles for neurofibromin in skeletal development and growth. Hum Mol Genet 16:874–886PubMedCrossRef Kolanczyk M, Kossler N, Kühnisch J, Lavitas L, Stricker S, Wilkening U, Manjubala I, Fratzl P, Spörle R, Herrmann BG, Parada LF, Kornak U, Mundlos S (2007) Multiple roles for neurofibromin in skeletal development and growth. Hum Mol Genet 16:874–886PubMedCrossRef
22.
go back to reference Korf BR, Henson JW, Stemmer-Rachamimov A (2005) Case records of the Massachusetts General Hospital. Case 13–2005. A 48-year-old man with weakness of the limbs and multiple tumors of spinal nerves. N Engl J Med 352:1800–1808PubMedCrossRef Korf BR, Henson JW, Stemmer-Rachamimov A (2005) Case records of the Massachusetts General Hospital. Case 13–2005. A 48-year-old man with weakness of the limbs and multiple tumors of spinal nerves. N Engl J Med 352:1800–1808PubMedCrossRef
23.
go back to reference Kretzschmar M, Doody J, Massagué J (1997) Opposing BMP and EGF signalling pathways converge on the TGF-beta family mediator Smad1. Nature 389:618–622PubMedCrossRef Kretzschmar M, Doody J, Massagué J (1997) Opposing BMP and EGF signalling pathways converge on the TGF-beta family mediator Smad1. Nature 389:618–622PubMedCrossRef
24.
go back to reference Kuorilehto T, Nissinen M, Koivunen J, Benson MD, Peltonen J (2004) NF1 tumor suppressor protein and mRNA in skeletal tissues of developing and adult normal mouse and NF1-deficient embryos. J Bone Miner Res 19:983–989PubMedCrossRef Kuorilehto T, Nissinen M, Koivunen J, Benson MD, Peltonen J (2004) NF1 tumor suppressor protein and mRNA in skeletal tissues of developing and adult normal mouse and NF1-deficient embryos. J Bone Miner Res 19:983–989PubMedCrossRef
25.
go back to reference Kuorilehto T, Pöyhönen M, Bloigu R, Heikkinen J, Väänänen K, Peltonen J (2005) Decreased bone mineral density and content in neurofibromatosis type 1: lowest local values are located in the load-carrying parts of the body. Osteoporos Int 16:928–936PubMedCrossRef Kuorilehto T, Pöyhönen M, Bloigu R, Heikkinen J, Väänänen K, Peltonen J (2005) Decreased bone mineral density and content in neurofibromatosis type 1: lowest local values are located in the load-carrying parts of the body. Osteoporos Int 16:928–936PubMedCrossRef
26.
go back to reference Lammert M, Kappler M, Mautner VF, Lammert K, Störkel S, Friedman JM, Atkins D (2005) Decreased bone mineral density in patients with neurofibromatosis 1. Osteoporos Int 16:1161–1166PubMedCrossRef Lammert M, Kappler M, Mautner VF, Lammert K, Störkel S, Friedman JM, Atkins D (2005) Decreased bone mineral density in patients with neurofibromatosis 1. Osteoporos Int 16:1161–1166PubMedCrossRef
27.
go back to reference Lee MJ, Stephenson DA (2007) Recent developments in neurofibromatosis type 1. Curr Opin Neurol 20:135–141PubMedCrossRef Lee MJ, Stephenson DA (2007) Recent developments in neurofibromatosis type 1. Curr Opin Neurol 20:135–141PubMedCrossRef
29.
go back to reference Miyazaki T, Katagiri H, Kanegae Y, Takayanagi H, Sawada Y, Yamamoto A, Pando MP, Asano T, Verma IM, Oda H, Nakamura K, Tanaka S (2000) Reciprocal role of ERK and NF-kappaB pathways in survival and activation of osteoclasts. J Cell Biol 148:333–342PubMedCrossRef Miyazaki T, Katagiri H, Kanegae Y, Takayanagi H, Sawada Y, Yamamoto A, Pando MP, Asano T, Verma IM, Oda H, Nakamura K, Tanaka S (2000) Reciprocal role of ERK and NF-kappaB pathways in survival and activation of osteoclasts. J Cell Biol 148:333–342PubMedCrossRef
30.
go back to reference Morrissy RT, Riseborough EJ, Hall JE (1981) Congenital pseudarthrosis of the tibia. J Bone Joint Surg Br 63B:367–375 Morrissy RT, Riseborough EJ, Hall JE (1981) Congenital pseudarthrosis of the tibia. J Bone Joint Surg Br 63B:367–375
31.
go back to reference Nakamura H, Hirata A, Tsuji T, Yamamoto T (2003) Role of osteoclast extracellular signal-regulated kinase (ERK) in cell survival and maintenance of cell polarity. J Bone Miner Res 18:1198–1205PubMedCrossRef Nakamura H, Hirata A, Tsuji T, Yamamoto T (2003) Role of osteoclast extracellular signal-regulated kinase (ERK) in cell survival and maintenance of cell polarity. J Bone Miner Res 18:1198–1205PubMedCrossRef
32.
go back to reference Nakamura M, Udagawa N, Matsuura S, Mogi M, Nakamura H, Horiuchi H, Saito N, Hiraoka BY, Kobayashi Y, Takaoka K, Ozawa H, Miyazawa H, Takahashi N (2003) Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. Endocrinology 144:5441–5449PubMedCrossRef Nakamura M, Udagawa N, Matsuura S, Mogi M, Nakamura H, Horiuchi H, Saito N, Hiraoka BY, Kobayashi Y, Takaoka K, Ozawa H, Miyazawa H, Takahashi N (2003) Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. Endocrinology 144:5441–5449PubMedCrossRef
33.
go back to reference Nakayama K, Tamura Y, Suzawa M, Harada S, Fukumoto S, Kato M, Miyazono K, Rodan GA, Takeuchi Y, Fujita T (2003) Receptor tyrosine kinases inhibit bone morphogenetic protein-Smad responsive promoter activity and differentiation of murine MC3T3-E1 osteoblast-like cells. J Bone Miner Res 18:827–835PubMedCrossRef Nakayama K, Tamura Y, Suzawa M, Harada S, Fukumoto S, Kato M, Miyazono K, Rodan GA, Takeuchi Y, Fujita T (2003) Receptor tyrosine kinases inhibit bone morphogenetic protein-Smad responsive promoter activity and differentiation of murine MC3T3-E1 osteoblast-like cells. J Bone Miner Res 18:827–835PubMedCrossRef
34.
go back to reference The Consensus Development Panel (1994) National Institutes of Health Consensus Development Conference Statement on Acoustic Neuroma, 11–13 December 1991. Arch Neurol 51:201–207 The Consensus Development Panel (1994) National Institutes of Health Consensus Development Conference Statement on Acoustic Neuroma, 11–13 December 1991. Arch Neurol 51:201–207
35.
go back to reference Reed AA, Joyner CJ, Brownlow HC, Simpson AH (2002) Human atrophic fracture non-unions are not avascular. J Orthop Res 20:593–599PubMedCrossRef Reed AA, Joyner CJ, Brownlow HC, Simpson AH (2002) Human atrophic fracture non-unions are not avascular. J Orthop Res 20:593–599PubMedCrossRef
37.
go back to reference Schindeler A, Little DG (2008) Recent insights into bone development, homeostasis, and repair in type 1 neurofibromatosis (NF1). Bone 42:616–622PubMedCrossRef Schindeler A, Little DG (2008) Recent insights into bone development, homeostasis, and repair in type 1 neurofibromatosis (NF1). Bone 42:616–622PubMedCrossRef
38.
go back to reference Seitz S, Schnabel C, Busse B, Schmidt HU, Beil FT, Friedrich RE, Schinke T, Mautner VF, Amling M (2010) High bone turnover and accumulation of osteoid in patients with neurofibromatosis 1. Osteoporos Int 21:119–127PubMedCrossRef Seitz S, Schnabel C, Busse B, Schmidt HU, Beil FT, Friedrich RE, Schinke T, Mautner VF, Amling M (2010) High bone turnover and accumulation of osteoid in patients with neurofibromatosis 1. Osteoporos Int 21:119–127PubMedCrossRef
39.
go back to reference Shapira S, Barkan B, Friedman E, Kloog Y, Stein R (2007) The tumor suppressor neurofibromin confers sensitivity to apoptosis by Ras-dependent and Ras-independent pathways. Cell Death Differ 14:895–906PubMed Shapira S, Barkan B, Friedman E, Kloog Y, Stein R (2007) The tumor suppressor neurofibromin confers sensitivity to apoptosis by Ras-dependent and Ras-independent pathways. Cell Death Differ 14:895–906PubMed
40.
go back to reference Stevenson DA, Zhou H, Ashrafi S, Messiaen LM, Carey JC, DʼAstous JL, Santora SD, Viskochil DH (2006) Double inactivation of NF1 in tibial pseudarthrosis. Am J Hum Genet 79:143–148PubMedCrossRef Stevenson DA, Zhou H, Ashrafi S, Messiaen LM, Carey JC, DʼAstous JL, Santora SD, Viskochil DH (2006) Double inactivation of NF1 in tibial pseudarthrosis. Am J Hum Genet 79:143–148PubMedCrossRef
41.
go back to reference Viskochil D (2002) Genetics of neurofibromatosis 1 and the NF1 gene. J Child Neurol 17:562–570 discussion 571–572, 646–651PubMedCrossRef Viskochil D (2002) Genetics of neurofibromatosis 1 and the NF1 gene. J Child Neurol 17:562–570 discussion 571–572, 646–651PubMedCrossRef
42.
go back to reference Wada T, Nakashima T, Hiroshi N, Penninger JM (2006) RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 12:17–25PubMedCrossRef Wada T, Nakashima T, Hiroshi N, Penninger JM (2006) RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 12:17–25PubMedCrossRef
43.
go back to reference Weinstein RS, Harris RL (1990) Hypercalcemic hyperparathyroidism and hypophosphatemic osteomalacia complicating neurofibromatosis. Calcif Tissue Int 46:361–366PubMedCrossRef Weinstein RS, Harris RL (1990) Hypercalcemic hyperparathyroidism and hypophosphatemic osteomalacia complicating neurofibromatosis. Calcif Tissue Int 46:361–366PubMedCrossRef
44.
go back to reference Writing Group for the ISCD Position Development Conference (2004) Position statement : executive summary. J Clin Densitom 7:7–12 Writing Group for the ISCD Position Development Conference (2004) Position statement : executive summary. J Clin Densitom 7:7–12
45.
go back to reference Yang FC, Chen S, Robling AG, Yu X, Nebesio TD, Yan J, Morgan T, Li X, Yuan J, Hock J, Ingram DA, Clapp DW (2006) Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions. J Clin Invest 116:2880–2891PubMedCrossRef Yang FC, Chen S, Robling AG, Yu X, Nebesio TD, Yan J, Morgan T, Li X, Yuan J, Hock J, Ingram DA, Clapp DW (2006) Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions. J Clin Invest 116:2880–2891PubMedCrossRef
46.
go back to reference Young H, Hyman S, North K (2002) Neurofibromatosis 1: clinical review and exceptions to the rules. J Child Neurol 17:613–621PubMedCrossRef Young H, Hyman S, North K (2002) Neurofibromatosis 1: clinical review and exceptions to the rules. J Child Neurol 17:613–621PubMedCrossRef
47.
go back to reference Zhu Y, Parada LF (2001) Neurofibromin, a tumor suppressor in the nervous system. Exp Cell Res 264:19–28PubMedCrossRef Zhu Y, Parada LF (2001) Neurofibromin, a tumor suppressor in the nervous system. Exp Cell Res 264:19–28PubMedCrossRef
Metadata
Title
Bone mineral metabolism in patients with neurofibromatosis type 1 (von Recklingausen disease)
Authors
Luigi Petramala
Sandra Giustini
Laura Zinnamosca
Cristiano Marinelli
Luciano Colangelo
Giuseppina Cilenti
Maria Chiara Formicuccia
Emilio D’Erasmo
Stefano Calvieri
Claudio Letizia
Publication date
01-05-2012
Publisher
Springer-Verlag
Published in
Archives of Dermatological Research / Issue 4/2012
Print ISSN: 0340-3696
Electronic ISSN: 1432-069X
DOI
https://doi.org/10.1007/s00403-011-1191-3

Other articles of this Issue 4/2012

Archives of Dermatological Research 4/2012 Go to the issue